ArticleBMC cancer2026
Sexual dysfunction among melanoma survivors: a scoping review of current evidence and clinical gaps.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sexual health is a fundamental component of quality of life that is frequently compromised in cancer patients. In melanoma care, these issues remain under addressed despite increasing survivorship. This scoping review aimed to map the current literature on sexual health concerns in melanoma patients. Following PRISMA-ScR guidelines, five databases were searched (2010-2025). Ten studies met the inclusion criteria, including cross-sectional, qualitative, and systematic reviews. Sexual dysfunction affected up to 52% of melanoma patients, with higher prevalence in men (68.9%) than women (41.3%). Contributing factors included visible scarring, hormonal imbalances (e.g., testosterone deficiency in 69% of men receiving immunotherapy), body image concerns, anxiety, and depression. Women were more affected by body image and recurrence anxiety, while men experienced higher rates of treatment-induced hypogonadism. In one cross-sectional study (n = 75), sexual dysfunction was reported in up to 52% of melanoma patients, with higher rates in men (68.9%) than women (41.3%); however, these estimates are based on limited data and should not be generalized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.